Walleye Capital LLC Tg Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$17.21 - $25.28 $721,099 - $1.06 Million	-41,900 Reduced 58.19%	30,100 $704,000
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $576,756 - $830,927	43,300 Added 150.87%	72,000 $1.28 Million
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $253,890 - $415,350	19,500 Added 211.96%	28,700 $436,000
Q4 2023 Feb 14, 2024	SELL	$6.68 - $18.81 $219,772 - $618,849	-32,900 Reduced 78.15%	9,200 $157,000
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $274,208 - $869,200	32,800 Added 352.69%	42,100 $351,000
Q2 2023 Aug 14, 2023	SELL	$15.48 - $35.0 $60,372 - $136,500	-3,900 Reduced 29.55%	9,300 $231,000
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $135,036 - $255,288	13,200 New	13,200 $198,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.